Alterity Therapeutics Stock Probability of Future Stock Price Finishing Over 21.22
ATHE Stock | USD 2.32 0.16 6.45% |
Alterity |
Alterity Therapeutics Target Price Odds to finish over 21.22
The tendency of Alterity Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
Current Price | Horizon | Target Price | Odds to move over $ 21.22 or more in 90 days |
2.32 | 90 days | 21.22 | close to zero percent |
Based on a normal probability distribution, the odds of Alterity Therapeutics to move over $ 21.22 or more in 90 days from now is close to zero percent (This Alterity Therapeutics probability density function shows the probability of Alterity Stock to fall within a particular range of prices over 90 days) . Probability of Alterity Therapeutics price to stay between its current price of $ 2.32 and $ 21.22 at the end of the 90-day period is near 1 .
Given the investment horizon of 90 days the stock has the beta coefficient of 1.09 . This suggests Alterity Therapeutics market returns are highly-sensitive to returns on the market. As the market goes up or down, Alterity Therapeutics is expected to follow. Additionally Alterity Therapeutics has an alpha of 0.8928, implying that it can generate a 0.89 percent excess return over Dow Jones Industrial after adjusting for the inherited market risk (beta). Alterity Therapeutics Price Density |
Price |
Predictive Modules for Alterity Therapeutics
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Alterity Therapeutics. Regardless of method or technology, however, to accurately forecast the stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Alterity Therapeutics Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Alterity Therapeutics is not an exception. The market had few large corrections towards the Alterity Therapeutics' value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Alterity Therapeutics, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Alterity Therapeutics within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | 0.89 | |
β | Beta against Dow Jones | 1.09 | |
σ | Overall volatility | 0.28 | |
Ir | Information ratio | 0.16 |
Alterity Therapeutics Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Alterity Therapeutics for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Alterity Therapeutics can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.Alterity Therapeutics is way too risky over 90 days horizon | |
Alterity Therapeutics appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 4.02 M. Net Loss for the year was (19.12 M) with profit before overhead, payroll, taxes, and interest of 3.63 M. | |
Alterity Therapeutics currently holds about 34.81 M in cash with (12.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87. | |
Alterity Therapeutics has a poor financial position based on the latest SEC disclosures | |
Latest headline from thelincolnianonline.com: Prana Capital Management LP Buys 16,495 Shares of Adobe Inc. |
Alterity Therapeutics Price Density Drivers
Market volatility will typically increase when nervous long traders begin to feel the short-sellers pressure to drive the market lower. The future price of Alterity Stock often depends not only on the future outlook of the current and potential Alterity Therapeutics' investors but also on the ongoing dynamics between investors with different trading styles. Because the market risk indicators may have small false signals, it is better to identify suitable times to hedge a portfolio using different long/short signals. Alterity Therapeutics' indicators that are reflective of the short sentiment are summarized in the table below.
Common Stock Shares Outstanding | 6.1 M | |
Cash And Short Term Investments | 12.6 M |
Alterity Therapeutics Technical Analysis
Alterity Therapeutics' future price can be derived by breaking down and analyzing its technical indicators over time. Alterity Stock technical analysis helps investors analyze different prices and returns patterns as well as diagnose historical swings to determine the real value of Alterity Therapeutics. In general, you should focus on analyzing Alterity Stock price patterns and their correlations with different microeconomic environments and drivers.
Alterity Therapeutics Predictive Forecast Models
Alterity Therapeutics' time-series forecasting models is one of many Alterity Therapeutics' stock analysis techniques aimed to predict future share value based on previously observed values. Time-series forecasting models are widely used for non-stationary data. Non-stationary data are called the data whose statistical properties, e.g., the mean and standard deviation, are not constant over time, but instead, these metrics vary over time. This non-stationary Alterity Therapeutics' historical data is usually called time series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the stock market movement and maximize returns from investment trading.
Things to note about Alterity Therapeutics
Checking the ongoing alerts about Alterity Therapeutics for important developments is a great way to find new opportunities for your next move. Our stock alerts and notifications screener for Alterity Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.
Alterity Therapeutics is way too risky over 90 days horizon | |
Alterity Therapeutics appears to be risky and price may revert if volatility continues | |
The company reported the previous year's revenue of 4.02 M. Net Loss for the year was (19.12 M) with profit before overhead, payroll, taxes, and interest of 3.63 M. | |
Alterity Therapeutics currently holds about 34.81 M in cash with (12.61 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.87. | |
Alterity Therapeutics has a poor financial position based on the latest SEC disclosures | |
Latest headline from thelincolnianonline.com: Prana Capital Management LP Buys 16,495 Shares of Adobe Inc. |
Check out Alterity Therapeutics Backtesting, Alterity Therapeutics Valuation, Alterity Therapeutics Correlation, Alterity Therapeutics Hype Analysis, Alterity Therapeutics Volatility, Alterity Therapeutics History as well as Alterity Therapeutics Performance. For information on how to trade Alterity Stock refer to our How to Trade Alterity Stock guide.You can also try the Bond Analysis module to evaluate and analyze corporate bonds as a potential investment for your portfolios..
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Alterity Therapeutics. If investors know Alterity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Alterity Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.07) | Revenue Per Share 0.6 | Quarterly Revenue Growth 0.384 | Return On Assets (0.53) | Return On Equity (1.04) |
The market value of Alterity Therapeutics is measured differently than its book value, which is the value of Alterity that is recorded on the company's balance sheet. Investors also form their own opinion of Alterity Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Alterity Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Alterity Therapeutics' market value can be influenced by many factors that don't directly affect Alterity Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Alterity Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Alterity Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Alterity Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.